WuXi XDC Cayman Inc. is a contract research, development and manufacturing organization (CRDMO) focused on antibody-drug conjugates (ADCs) and other bioconjugates. It provides integrated, end-to-end services that encompass discovery, development and cGMP manufacturing of key intermediates such as chemical payload-linkers and biologics, as well as bioconjugate drug substances and drug products.
Formed as a joint venture between WuXi Biologics and WuXi STA, the company maintains its headquarters in Wuxi, China, with additional operations in Shanghai and Changzhou. It has pursued international expansion, including facilities in Singapore. WuXi XDC Cayman Inc. is listed on the Hong Kong Stock Exchange.
Also known as 藥明合聯生物技術有限公司.
Modular DP facility in Tuas topped out; 30,000 sqm, adds 120,000 L capacity and targets ~100 million PFS/vial units per year with operations slated for 2027.
